Genelux Co. (NASDAQ:GNLX) Short Interest Update

Genelux Co. (NASDAQ:GNLX) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,040,000 shares, a decrease of 7.1% from the September 30th total of 1,120,000 shares. Currently, 3.8% of the shares of the stock are short sold. Based on an average trading volume of 154,200 shares, the short-interest ratio is presently 6.7 days.

Analysts Set New Price Targets

GNLX has been the subject of several recent research reports. Guggenheim initiated coverage on Genelux in a research note on Tuesday. They issued a “buy” rating and a $8.00 price target for the company. Roth Mkm started coverage on shares of Genelux in a research report on Tuesday, August 27th. They set a “buy” rating and a $10.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of Genelux in a research report on Thursday, August 15th. Finally, Roth Capital raised shares of Genelux to a “strong-buy” rating in a research note on Tuesday, August 27th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $18.75.

Genelux Price Performance

Shares of Genelux stock traded down $0.11 on Thursday, hitting $3.22. 138,888 shares of the company’s stock traded hands, compared to its average volume of 183,818. The company has a market capitalization of $111.20 million, a price-to-earnings ratio of -3.35 and a beta of -1.54. The company has a fifty day moving average of $2.50 and a two-hundred day moving average of $2.63. Genelux has a one year low of $1.60 and a one year high of $18.01.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Equities research analysts anticipate that Genelux will post -0.89 earnings per share for the current year.

Insider Activity

In related news, major shareholder Aladar Szalay sold 40,000 shares of Genelux stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $2.29, for a total transaction of $91,600.00. Following the sale, the insider now directly owns 1,099,821 shares in the company, valued at $2,518,590.09. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 331,062 shares of company stock worth $736,831. Insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Genelux

Large investors have recently bought and sold shares of the stock. Highbridge Capital Management LLC bought a new position in shares of Genelux during the 2nd quarter worth about $1,231,000. Armistice Capital LLC bought a new position in Genelux in the second quarter worth approximately $1,755,000. Affinity Asset Advisors LLC acquired a new stake in Genelux in the second quarter valued at approximately $195,000. Cubist Systematic Strategies LLC bought a new stake in shares of Genelux during the second quarter valued at approximately $56,000. Finally, AMG National Trust Bank lifted its holdings in shares of Genelux by 49.7% in the 2nd quarter. AMG National Trust Bank now owns 75,351 shares of the company’s stock worth $147,000 after purchasing an additional 25,000 shares in the last quarter. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.